Figure 1.

MV130 prophylactic administration protects against SARS-CoV-2 infection. (A) Scheme of immunotherapy administration. Mice were i.n. administered with excipient or MV130 three times per week for 2 weeks. After a resting week, mice were analyzed or infected. (B–D) Bronchoalveolar lavage (BAL) was obtained from excipient and MV130-treated C57BL/6 mice. Quantitative analysis of total live CD45⁺ cells (B), different myeloid (C) or lymphoid (D) immune populations identified by FACS. AMs, alveolar macrophages; cDC1s, type 1 conventional dendritic cells; cDC2s, type 2 conventional dendritic cells. N=2. (E, F) K18-hACE2 mice received excipient or MV130 as indicated in (A). One week later they were i.n. infected with 10⁴ PFU of SARS-CoV-2 (MAD6 strain). Weight (E) and survival (F) were monitored daily. (E) Numbers in the graph indicate remaining alive mice. N=2. (n=15 excipient; n=12 MV130). D.p.i., days post infection. (B–E) Data shown as mean ± SEM. *p < 0.05; **p< 0.01; ***p < 0.001, Student’s t test comparing excipient versus MV130. (F) *p < 0.05, Mantel-Cox test.